

Cell line name	CMDi002-A
----------------	-----------

Purpose

The purpose of this Cell Line Information Pack (CLIP) is to communicate cell line specific information to potential users of the cell line, and to confirm that a User has received it upon the purchase of an EBiSC cell line.

Information

The CLIP may provide a variety of types of information related to an individual cell line. Of particular importance are Third Party Obligations (TPOs), which are ethical or legal obligations of a Depositor related to the use of the cell line. TPOs may impose ethical or legal limitations on the ability of a User to use the cell line, or require steps to be taken before it can be used. TPOs are likely to be:

- Obligations under license to an intellectual property rights (patent) holder, or
- Restrictions on use imposed by the donor of the primary tissue from which the cell line was made.

Third Party Obligations: donor consent provisions

This iPSC line is only to be used in research into muscular dystrophy.

Third Party Obligations: IP or license provisions

iPS-AJ: This EBiSC Cell line was generated under the technology disclosed in patents related to iPS cells which are owned by Kyoto University and are licensable from iPS Academia Japan., Inc. ("iPS AJ"). Commercial user (for-profit entity) acknowledges that, prior to receipt and use of this EBiSC Cell line, such commercial user needs to have an appropriate patent license from iPS AJ even for its research use. Academic user (academic or not-for-profit entity) acknowledges that such academic user does not need a patent license from iPS AJ for its research use, provided, however, that when such academic user uses this EBiSC Cell line for other than its independent research use, such academic user acknowledges that the academic user might need to obtain an appropriate patent license from iPS AJ. For inquiries to iPS AJ, please contact at license@ips-ac.co.jp.

Recipient acknowledges that the Cells and the methods used to create them embody intellectual property deemed to be of significant value to FCDI and its licensors, and that such intellectual property is protected by the law of patents, copyrights, trade secrets, and other laws. Recipient acknowledges and agrees that neither these terms nor the receipt of the Cells by Recipient shall be construed as a transfer of any title or the grant of any rights in, to or under the intellectual property embodied in the Cells owned or licensed by FCDI. The Cells are covered by certain pending patents and/or patents, which may be found under MyCell Products at <https://fujifilmcdi.com/about-us/patents/>. The Cells are also covered by a number of patents and pending patents licensed to FCDI from iPS Academia Japan Inc., including Japanese Patent Nos. 4183742, 4411362, 4411363. Neither FCDI nor its licensor, iPS Academia Japan, Inc. makes any warranty or representation as to the validity, scope, or enforceability of the patents owned by or licensed to FCDI. Recipient has a limited license to use the Cells and derivatives solely for Recipient's internal academic research purposes, subject to these Use Restrictions. No other right, express or implied, is conveyed by the provision of the Cells. In particular, no right to make, have made, offer to sell, or sell the Cells or derivatives is implied by the provision of the Cells. The license granted herein does not imply or convey the right to use the Cells or derivatives in combination with any other product(s) whose manufacture,

www.EBiSC.org



In case of queries, please get in touch via: Contact@EBiSC.org.

Cell line name

CMDi002-A

sale, or use is covered by any patent owned by any third party. Recipient must use the Cells and derivatives solely for Recipient's internal academic research purposes. Not by way of limitation of the immediately preceding provision but by way of example, Recipient may not use the Cells or derivatives for commercial purposes of any kind, including without limitation, to manufacture of any products or to provide services to a third party, or for sponsored research of any kind where intellectual property rights or options to intellectual property rights may be granted to the commercial sponsor of such research. Recipient may propagate no more than 120,000,000 live Cells of any one line at any one time (approximately the number of cells in 10 conventional culture plates) at the Institution. Recipient shall not sell or transfer the Cells or derivatives. The Cells must be used in accordance with any applicable FCDI User's Guide. Recipient may differentiate the Cells using publicly available or its own differentiation methods. Recipient shall not use FCDI's patented and/or proprietary methods for differentiation of the Cells, and (not by way of limitation of what is provided above but by way of example) no license to use such methods is conveyed herein. Recipient shall not reverse engineer the Cells in any way. Recipient shall not use the Cells or derivatives in humans, in clinical trials or for diagnostic purposes involving human subjects, for any therapeutic use or investigational use, or for any purpose in contravention of any applicable law, regulation, ordinance, institutional review board approved protocol, or privacy office approval. 3

Data Processing

The Personal Data which can be Processed in view of this EAU are

- Genetic Data including STR profiles: Yes
- Clinical Data: Yes
- Biometric Data: No
- Other: No

The categories of the Data Subjects to which the Personal Data relate that are Processed are

- Study participants: Yes
- Other: No

The nature and the purpose of the Processing of the Personal Data are as follows:

Collecting / storing / analysing / sharing Personal data for generation / characterisation / qualification / use / distribution of iPSC lines / and iPSC derivatives

Other information

Any publications or public dissemination of results using EBiSC iPSCs should be accompanied by the following acknowledgement: "The EBiSC Bank acknowledges Cure CMD and LGMD2I Fund as the source of the human induced pluripotent cell line CMDi002-A which was generated with support from the EBiSC2 project. The EBiSC has received support from the Innovative Medicines Initiative (IMI) Joint Undertaking (JU) under grant agreement n°115582 and from the IMI-2 JU under grant agreement No 821362, resources of which are composed of financial



In case of queries, please get in touch via: Contact@EBiSC.org.

Cell line name	CMDi002-A
----------------	-----------

contribution from the European Union's Seventh Framework Programme (FP7/2007-2013), European Union's Horizon 2020 research and innovation programme and EFPIA."

SIGN AND RETURN THIS DOCUMENT WITH YOUR COMPLETED ACCESS AND USE AGREEMENT

User acknowledgement

Please sign below to indicate that you have read and acknowledge the information contained in this CLIP.

Name _____ Position _____

Signature _____ Date _____

www.EBiSC.org



In case of queries, please get in touch via: Contact@EBiSC.org.